{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:08:05Z","timestamp":1779192485245,"version":"3.51.4"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.remnie.2026.500306","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T17:15:20Z","timestamp":1773681320000},"page":"500306","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Renal and Hematologic Toxicity Profile of [177] Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT): A Retrospective Cohort Study"],"prefix":"10.1016","author":[{"given":"M.","family":"Yal\u00e7\u0131nkaya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Demir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Kara\u00e7avu\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Demir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.remnie.2026.500306_bib0005","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s40291-022-00594-2","article-title":"Lutetium Lu 177 vipivotide tetraxetan: first approval","volume":"26","author":"Keam","year":"2022","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.remnie.2026.500306_bib0010","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.3390\/ph15101292","article-title":"[177Lu]Lu-PSMA-617 (PluvictoTM): the first FDA-approved radiotherapeutical for treatment of prostate cancer","volume":"15","author":"Hennrich","year":"2022","journal-title":"Pharmaceuticals (Basel)."},{"key":"10.1016\/j.remnie.2026.500306_bib0015","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2967\/jnumed.116.183194","article-title":"German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients","volume":"58","author":"Rahbar","year":"2017","journal-title":"J Nucl Med."},{"key":"10.1016\/j.remnie.2026.500306_bib0020","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","article-title":"Joint EANM\/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)","volume":"50","author":"Kratochwil","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remnie.2026.500306_bib0025","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1080\/15384047.2022.2037985","article-title":"Lutetium-177-PSMA-617: a vision of the future","volume":"23","author":"Chandran","year":"2022","journal-title":"Cancer Biol Ther."},{"key":"10.1016\/j.remnie.2026.500306_bib0030","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.2967\/jnumed.115.168443","article-title":"177Lu-Labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy","volume":"57","author":"Baum","year":"2016","journal-title":"J Nucl Med."},{"key":"10.1016\/j.remnie.2026.500306_bib0035","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/MOU.0000000000000486","article-title":"Prostate-specific membrane antigen theranostics: therapy with lutetium-177","volume":"28","author":"Ferdinandus","year":"2018","journal-title":"Curr Opin Urol."},{"key":"10.1016\/j.remnie.2026.500306_bib0040","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3390\/biomedicines9040430","article-title":"177Lu-PSMA therapy in metastatic castration-resistant prostate cancer","volume":"9","author":"Sanli","year":"2021","journal-title":"Biomedicines."},{"key":"10.1016\/j.remnie.2026.500306_bib0045","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.eururo.2018.11.016","article-title":"Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer","volume":"75","author":"Heck","year":"2019","journal-title":"Eur Urol."},{"key":"10.1016\/j.remnie.2026.500306_bib0050","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00259-017-3681-9","article-title":"The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer","volume":"44","author":"Yordanova","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remnie.2026.500306_bib0055","first-page":"81","article-title":"Prostate-specific membrane antigen expression in normal and malignant human tissues","volume":"3","author":"Silver","year":"1997","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.remnie.2026.500306_bib0060","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1007\/s00259-015-3125-3","article-title":"Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer","volume":"42","author":"Kabasakal","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remnie.2026.500306_bib0065","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s00259-015-3174-7","article-title":"Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer","volume":"43","author":"Delker","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remnie.2026.500306_bib0070","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.240427","article-title":"Automated CT measurement of total kidney volume for predicting renal function decline after 177Lu prostate-specific membrane Antigen-I&T radioligand therapy","volume":"314","author":"Steinhelfer","year":"2025","journal-title":"Radiology."},{"key":"10.1016\/j.remnie.2026.500306_bib0075","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.2967\/jnumed.115.171397","article-title":"PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-Labeled PSMA-617","volume":"57","author":"Kratochwil","year":"2016","journal-title":"J Nucl Med."},{"key":"10.1016\/j.remnie.2026.500306_bib0080","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/ckj\/sfz101","article-title":"Renal outcomes of radioligand therapy: experience of 177lutetium-prostate-specific membrane antigen ligand therapy in metastatic castrate-resistant prostate cancer","volume":"13","author":"Gallyamov","year":"2019","journal-title":"Clin Kidney J."},{"key":"10.1016\/j.remnie.2026.500306_bib0085","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2214\/AJR.18.20845","article-title":"Radioligand therapy with 177Lu-PSMA for metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"213","author":"Yadav","year":"2019","journal-title":"AJR Am J Roentgenol."},{"key":"10.1016\/j.remnie.2026.500306_bib0090","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2967\/jnumed.118.219352","article-title":"Dosimetry of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes","volume":"60","author":"Violet","year":"2019","journal-title":"J Nucl Med."},{"key":"10.1016\/j.remnie.2026.500306_bib0095","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","article-title":"[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study","volume":"19","author":"Hofman","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.remnie.2026.500306_bib0100","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med."},{"key":"10.1016\/j.remnie.2026.500306_bib0105","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1158\/1078-0432.CCR-20-4298","article-title":"Lutetium-177-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer: a prospective pilot study","volume":"27","author":"Priv\u00e9","year":"2021","journal-title":"Clin Cancer Res."}],"container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253808926000352?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253808926000352?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T11:38:33Z","timestamp":1779190713000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2253808926000352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":21,"alternative-id":["S2253808926000352"],"URL":"https:\/\/doi.org\/10.1016\/j.remnie.2026.500306","relation":{},"ISSN":["2253-8089"],"issn-type":[{"value":"2253-8089","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Renal and Hematologic Toxicity Profile of [177] Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT): A Retrospective Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.remnie.2026.500306","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.remn.2026.500306","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedad Espa\u00f1ola de Medicina Nuclear e Imagen Molecular. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"500306"}}